Scarica l'app Stockscreener
3.02
0.67%
0.02
Pre-mercato:
3.02
Tvardi Therapeutics Inc Borsa (TVRD) Ultime notizie
Tvardi Therapeutics (NASDAQ:TVRD) Cut to Sell at Wall Street Zen - Defense World
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium - Sahm
BTIG Research Reaffirms Buy Rating for Tvardi Therapeutics (NASDAQ:TVRD) - Defense World
Tvardi management heads to New York for Apr. 14 biotech symposium - stocktitan.net
Barclays Lowers Price Target for Tvardi Therapeutics (TVRD) | TV - GuruFocus
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development - TipRanks
Tvardi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tvardi Therapeutics (TVRD) Sees Price Target Cut by Piper Sandler | TVRD Stock News - GuruFocus
Piper Sandler cuts Tvardi Therapeutics price target on trial timing - Investing.com
Tvardi Therapeutics (NASDAQ: TVRD) registers 2,084,117 resale shares; clinical updates - Stock Titan
Tvardi Therapeutics (NASDAQ: TVRD) adds auditor consent in S-1 amendment - stocktitan.net
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update - Bitget
Tvardi: Q4 Earnings Snapshot - WKYC
Tvardi Therapeutics (NASDAQ: TVRD) outlines STAT3 trial plans - Stock Titan
Tvardi (NASDAQ: TVRD) narrows 2025 loss and eyes key 2026 trial data - stocktitan.net
Tvardi lines up 2 drug readouts in 2026 with cash lasting into Q4 - stocktitan.net
Tvardi Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Tvardi Therapeutics Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Published on: 2026-03-31 03:05:34 - baoquankhu1.vn
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Consensus Price Target from Analysts - Defense World
Performance Recap: Will Tvardi Therapeutics Inc outperform during market rallies - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | TVRD | US1407553072 - marketscreener.com
Tvardi Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 69C | US1407553072 - marketscreener.com
Stop Loss: Is Tvardi Therapeutics Inc part of any major index2026 Short Interest & High Yield Equity Trading Tips - baoquankhu1.vn
Aug Swings: What hedge funds are buying Tvardi Therapeutics IncDollar Strength & Real-Time Sentiment Analysis - baoquankhu1.vn
Purchase/sale of business (net) of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Published on: 2026-03-12 05:56:22 - baoquankhu1.vn
Tvardi Therapeutics (TVRD) Stock Analysis Report | Financials & Insights - Benzinga Japan
What sentiment indicators say about Tvardi Therapeutics Inc. stockPortfolio Update Report & Free Community Consensus Stock Picks - Naître et grandir
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting - The Globe and Mail
Tvardi Therapeutics sets June 9, 2026 annual meeting; proxy and nomination deadlines announced - TradingView
[424B3] Tvardi Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Key deadlines for Tvardi Therapeutics (NASDAQ: TVRD) 2026 stockholder meeting - Stock Titan
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Brokerages - Defense World
Growth Report: Is Tvardi Therapeutics Inc attractive for institutional investorsInsider Selling & Entry Point Confirmation Alerts - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | 0HTC | US1407553072 - marketscreener.com
CARA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Free cash flow per share of Tvardi Therapeutics Inc. – FWB:69C - TradingView
Tvardi Therapeutics, Inc. (TVRD): Investor Outlook on the Biotech Company’s 125% Potential Upside - DirectorsTalk Interviews
Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics - Barchart
Analysts Are Bullish on These Healthcare Stocks: Inhibikase Therapeutics (IKT), MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
Head-To-Head Review: Tvardi Therapeutics (NASDAQ:TVRD) vs. InflaRx (NASDAQ:IFRX) - Defense World
MSN Money - MSN
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: Exploring a Potential 140% Upside in Biotechnology - DirectorsTalk Interviews
Will Tvardi Therapeutics Inc. (69C) stock sustain uptrend momentumTrade Performance Summary & Risk Managed Investment Entry Signals - mfd.ru
Will Tvardi Therapeutics Inc. outperform during market ralliesJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What is Tvardi Therapeutics Inc.’s book value per shareJuly 2025 Macro Moves & Long-Term Growth Plans - mfd.ru
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Look at the 129% Potential Upside in Biotech - DirectorsTalk Interviews
Published on: 2026-02-12 23:10:23 - mfd.ru
Will Tvardi Therapeutics Inc. stock maintain dividend yield2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate - Yahoo Finance
Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen - Defense World
Risk Report: Is BRLSW affected by consumer sentimentWeekly Gains Summary & Verified Entry Point Detection - baoquankhu1.vn
Tvardi Therapeutics (NASDAQ:TVRD) Raised to Strong-Buy at Lucid Cap Mkts - Defense World
Lucid Capital Markets upgrades Tvardi Therapeutics stock to Buy on valuation - Investing.com Nigeria
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital - TipRanks
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
Growth Report: Can Tvardi Therapeutics Inc sustain its profitabilityJuly 2025 Final Week & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
What is the long term forecast for Tvardi Therapeutics Inc. stockWeekly Stock Analysis & Capital Efficient Trade Techniques - mfd.ru
MACD Signal: What is the cash position of BEEPJuly 2025 Drop Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):